Arena Pharmaceuticals ( ARNA) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day up 0.7%. By the end of trading, Arena Pharmaceuticals fell 6 cents (-0.5%) to $11.05 on average volume. Throughout the day, 22.1 million shares of Arena Pharmaceuticals exchanged hands as compared to its average daily volume of 25 million shares. The stock ranged in price between $10.62-$11.52 after having opened the day at $11.01 as compared to the previous trading day's close of $11.11. Other company's within the Drugs industry that declined today were: Savient Pharmaceuticals ( SVNT), down 15.5%, Rexahn Pharmaceuticals ( RNN), down 13.5%, Tekmira Pharmaceuticals Corporation ( TKMR), down 13.4%, and Biosante Pharmaceuticals ( BPAX), down 12.9%.

Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. Arena Pharmaceuticals has a market cap of $2.2 billion and is part of the health care sector. Shares are up 497.9% year to date as of the close of trading on Monday. Currently there are two analysts that rate Arena Pharmaceuticals a buy, one analyst rates it a sell, and six rate it a hold.

TheStreet Ratings rates Arena Pharmaceuticals as a sell. Among the areas we feel are negative, one of the most important has been an overall disappointing return on equity.

On the positive front, StemCells ( STEM), up 106.9%, Peregrine Pharmaceuticals ( PPHM), up 26.4%, Allos Therapeutics ( ALTH), up 21.7%, and Hemispherx Biopharma ( HEB), up 20.5%, were all gainers within the drugs industry with Bristol-Myers Squibb Company ( BMY) being today's featured drugs industry winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).